Log in to search using one of your social media accounts:

 

CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival
CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival, Published online: 15 February 2018; doi:10.1038/s41408-018-0058-7CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 15, 2018 Category: Hematology Authors: Natasha Szuber Christy M. Finke Terra L. Lasho Michelle A. Elliott Curtis A. Hanson Animesh Pardanani Ayalew Tefferi Source Type: research

Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome
Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome, Published online: 15 February 2018; doi:10.1038/s41408-018-0060-0Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 15, 2018 Category: Hematology Authors: Chunyan Gu Carol Holman Ramakrishna Sompallae Xuefang Jing Michael Tomasson Dirk Hose Anja Seckinger Fenghuang Zhan Guido Tricot Hartmut Goldschmidt Ye Yang Siegfried Janz Source Type: research

The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma
The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma, Published online: 13 February 2018; doi:10.1038/s41408-018-0053-zThe small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 13, 2018 Category: Hematology Authors: Sara Canovas Nunes Martina Manzoni Marco Pizzi Elisa Mandato Marilena Carrino Laura Quotti Tubi Renato Zambello Fausto Adami Andrea Visentin Gregorio Baril à Livio Trentin Sabrina Manni Antonino Neri Gianpietro Semenzato Francesco Piazza Source Type: research

Chronic neutrophilic leukemia: new science and new diagnostic criteria
Chronic neutrophilic leukemia: new science and new diagnostic criteria, Published online: 13 February 2018; doi:10.1038/s41408-018-0049-8Chronic neutrophilic leukemia: new science and new diagnostic criteria (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 13, 2018 Category: Hematology Authors: Natasha Szuber Ayalew Tefferi Source Type: research

Rac1 is a novel therapeutic target in mantle cell lymphoma
Rac1 is a novel therapeutic target in mantle cell lymphoma, Published online: 12 February 2018; doi:10.1038/s41408-018-0052-0Rac1 is a novel therapeutic target in mantle cell lymphoma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 12, 2018 Category: Hematology Authors: Tian Tian Chengfeng Bi Ashley L. Hein Xuan Zhang Cheng Wang Songfei Shen Ji Yuan Timothy C. Greiner Charles Enke Julie Vose Ying Yan Kai Fu Source Type: research

Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts
Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts, Published online: 12 February 2018; doi:10.1038/s41408-018-0051-1Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 12, 2018 Category: Hematology Authors: Abhishek A. Mangaonkar Terra L. Lasho Christy M. Finke Naseema Gangat Aref Al-Kali Michelle A. Elliott Kebede H. Begna Hassan Alkhateeb Alexandra P. Wolanskyj-Spinner Curtis A. Hanson Rhett P. Ketterling William J. Hogan Animesh Pardanani Mark R. Litzow A Source Type: research

Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies
Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignanciesFinal results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies, Published online: 12 February 2018; doi:10.1038/s41408-018-0055-xFinal results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 12, 2018 Category: Hematology Authors: Arnon P. Kater Sanne H. Tonino Marjolein Spiering Martine E D Chamuleau Roberto Liu Adeboye Henry Adewoye Jie Gao Lyndah Dreiling Yan Xin Jeanette K. Doorduijn Marie Jos é Kersten Source Type: research

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion, Published online: 09 February 2018; doi:10.1038/s41408-018-0054-yThe 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - February 9, 2018 Category: Hematology Authors: Tiziano Barbui J ürgen Thiele Heinz Gisslinger Hans Michael Kvasnicka Alessandro M. Vannucchi Paola Guglielmelli Attilio Orazi Ayalew Tefferi Source Type: research

Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers
Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers, Published online: 29 January 2018; doi:10.1038/s41408-018-0050-2Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 29, 2018 Category: Hematology Authors: Alissa Visram Christopher Bredeson David Allan Mitchell Sabloff Lothar Huebsch Jason Tay Natasha Kekre Sheryl McDiarmid Ranjeeta Mallick Alan Tinmouth Lisa Martin Linda Hamelin Dawn Maze Source Type: research

The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein-Barr virus presence and location within the tumor
The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein-Barr virus presence and location within the tumor, Published online: 26 January 2018; doi:10.1038/bcj.2017.102The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein-Barr virus presence and location within the tumor (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 26, 2018 Category: Hematology Authors: R Wu A Sattarzadeh B Rutgers A Diepstra A van den Berg L Visser Source Type: research

Prognostic impact of a past or synchronous second cancer in diffuse large B cell lymphoma
Prognostic impact of a past or synchronous second cancer in diffuse large B cell lymphoma, Published online: 25 January 2018; doi:10.1038/s41408-017-0043-6Prognostic impact of a past or synchronous second cancer in diffuse large B cell lymphoma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 25, 2018 Category: Hematology Authors: Kazuna Tanba Yoshiaki Chinen Hitoji Uchiyama Nobuhiko Uoshima Kazuho Shimura Shinichi Fuchida Miki Kiyota Mitsushige Nakao Yuji Shimura Tsutomu Kobayashi Shigeo Horiike Katsuya Wada Chihiro Shimazaki Hiroto Kaneko Yutaka Kobayashi Masafumi Taniwaki Junya Source Type: research

Del11q-positive CLL lymphocytes exhibit altered glutamine metabolism and differential response to GLS1 and glucose metabolism inhibition
Del11q-positive CLL lymphocytes exhibit altered glutamine metabolism and differential response to GLS1 and glucose metabolism inhibition, Published online: 24 January 2018; doi:10.1038/s41408-017-0039-2Del11q-positive CLL lymphocytes exhibit altered glutamine metabolism and differential response to GLS1 and glucose metabolism inhibition (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 24, 2018 Category: Hematology Authors: Gabriela Galicia-V ázquez Sarah Smith Raquel Aloyz Source Type: research

EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental
EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental, Published online: 22 January 2018; doi:10.1038/s41408-017-0045-4EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 22, 2018 Category: Hematology Authors: Mrinal M. Patnaik Rangit Vallapureddy Terra L. Lasho Katherine P. Hoversten Christy M. Finke Rhett Ketterling Curtis Hanson Naseema Gangat Ayalew Tefferi Source Type: research

Current applications of multiparameter flow cytometry in plasma cell disorders
Current applications of multiparameter flow cytometry in plasma cell disorders, Published online: 19 January 2018; doi:10.1038/bcj.2017.101Current applications of multiparameter flow cytometry in plasma cell disorders (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 19, 2018 Category: Hematology Authors: T Jelinek R Bezdekova M Zatopkova L Burgos M Simicek T Sevcikova B Paiva R Hajek Source Type: research

SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia
SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia, Published online: 19 January 2018; doi:10.1038/s41408-017-0036-5SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 19, 2018 Category: Hematology Authors: Patricia Johansson Ludger Klein-Hitpass Axel Choidas Peter Habenberger Bijan Mahboubi Baek Kim Anke Bergmann Ren é Scholtysik Martina Brauser Anna Lollies Reiner Siebert Thorsten Zenz Ulrich D ührsen Ralf K üppers Jan D ürig Source Type: research

Mutational heterogeneity of angioimmunoblastic T-cell lymphoma indicates distinct lymphomagenic pathways
Mutational heterogeneity of angioimmunoblastic T-cell lymphoma indicates distinct lymphomagenic pathways, Published online: 17 January 2018; doi:10.1038/s41408-017-0047-2Mutational heterogeneity of angioimmunoblastic T-cell lymphoma indicates distinct lymphomagenic pathways (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 17, 2018 Category: Hematology Authors: Mathijs Willemsen Myrurgia Abdul Hamid Bjorn Winkens Axel zur Hausen Source Type: research

Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia
Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia, Published online: 16 January 2018; doi:10.1038/s41408-017-0044-5Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 16, 2018 Category: Hematology Authors: Pablo Mozas Alfredo Rivas-Delgado Tycho Baumann Neus Villamor Valent ín Ortiz-Maldonado Marta Aymerich Dolors Costa Alba Navarro Eva Gin é Armando L ópez-Guillermo Emili Montserrat Julio Delgado Source Type: research

Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data
Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data, Published online: 16 January 2018; doi:10.1038/s41408-017-0038-3Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 16, 2018 Category: Hematology Authors: Arianna Ghirardi Alessandra Carobbio Arianna Masciulli Tiziano Barbui Source Type: research

Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response
Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response, Published online: 15 January 2018; doi:10.1038/s41408-017-0029-4Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 15, 2018 Category: Hematology Authors: Xueping Luo Zefeng Xu Bing Li Tiejun Qin Peihong Zhang Hongli Zhang Liwei Fang Lijuan Pan Naibo Hu Shiqiang Qu Yue Zhang Gang Huang Robert Peter Gale Zhijian Xiao Source Type: research

Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed?
Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed?, Published online: 12 January 2018; doi:10.1038/s41408-017-0046-3Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed? (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 12, 2018 Category: Hematology Authors: Maura Nicolosi Mythri Mudireddy Naseema Gangat Animesh Pardanani Curtis A. Hanson Rhett P. Ketterling Ayalew Tefferi Source Type: research

Pathogenesis of bone disease in multiple myeloma: from bench to bedside
Pathogenesis of bone disease in multiple myeloma: from bench to bedside, Published online: 12 January 2018; doi:10.1038/s41408-017-0037-4Pathogenesis of bone disease in multiple myeloma: from bench to bedside (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 12, 2018 Category: Hematology Authors: Evangelos Terpos Ioannis Ntanasis-Stathopoulos Maria Gavriatopoulou Meletios A. Dimopoulos Source Type: research

Polycythemia vera treatment algorithm 2018
Polycythemia vera treatment algorithm 2018, Published online: 10 January 2018; doi:10.1038/s41408-017-0042-7Polycythemia vera treatment algorithm 2018 (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 10, 2018 Category: Hematology Authors: Ayalew Tefferi Alessandro M. Vannucchi Tiziano Barbui Source Type: research

Essential thrombocythemia treatment algorithm 2018
Essential thrombocythemia treatment algorithm 2018, Published online: 10 January 2018; doi:10.1038/s41408-017-0041-8Essential thrombocythemia treatment algorithm 2018 (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 10, 2018 Category: Hematology Authors: Ayalew Tefferi Alessandro M. Vannucchi Tiziano Barbui Source Type: research

Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1
Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1, Published online: 10 January 2018; doi:10.1038/s41408-017-0040-9Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1 (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - January 10, 2018 Category: Hematology Authors: Caner Saygin Cassandra Hirsch Bartlomiej Przychodzen Mikkael A. Sekeres Betty K. Hamilton Matt Kalaycio Hetty E. Carraway Aaron T. Gerds Sudipto Mukherjee Aziz Nazha Ronald Sobecks Christopher Goebel Donna Abounader Jaroslaw P. Maciejewski Anjali S. Advan Source Type: research

Prognostic impacts and dynamic changes of cohesin complex gene mutations in de novo acute myeloid leukemia
Prognostic impacts and dynamic changes of cohesin complex gene mutations in de novo acute myeloid leukemia, Published online: 29 December 2017; doi:10.1038/s41408-017-0022-yPrognostic impacts and dynamic changes of cohesin complex gene mutations in de novo acute myeloid leukemia (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - December 29, 2017 Category: Hematology Authors: Cheng-Hong Tsai Hsin-An Hou Jih-Luh Tang Yuan-Yeh Kuo Yu-Chiao Chiu Chien-Chin Lin Chieh-Yu Liu Mei-Hsuan Tseng Tzung-Yi Lin Ming-Chih Liu Chia-Wen Liu Liang-In Lin Ming Yao Chi-Cheng Li Shang-Yi Huang Bor-Sheng Ko Szu-Chun Hsu Chien-Ting Lin Shang-Ju Wu Source Type: research

Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients
Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients, Published online: 27 December 2017; doi:10.1038/s41408-017-0035-6Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - December 27, 2017 Category: Hematology Authors: S. Cerquozzi D. Barraco T. Lasho C. Finke C. A. Hanson R. P. Ketterling A. Pardanani N. Gangat A. Tefferi Source Type: research

ANP32A dysregulation contributes to abnormal megakaryopoiesis in acute megakaryoblastic leukemia
ANP32A dysregulation contributes to abnormal megakaryopoiesis in acute megakaryoblastic leukemia, Published online: 22 December 2017; doi:10.1038/s41408-017-0031-xANP32A dysregulation contributes to abnormal megakaryopoiesis in acute megakaryoblastic leukemia (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - December 22, 2017 Category: Hematology Authors: Xueqin Sun Bin Lu Cuijuan Han Wanlin Qiu Qi Jin Dengju Li Qiubai Li Qiong Yang Qiang Wen Puneet Opal Ameet R. Kini John D. Crispino Zan Huang Source Type: research

Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes
Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes, Published online: 21 December 2017; doi:10.1038/s41408-017-0021-zAggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - December 21, 2017 Category: Hematology Authors: Y-T Tang D Wang H Luo M Xiao H-S Zhou D Liu S-P Ling N Wang X-L Hu Y Luo X Mao Q-L Ao J Huang W Zhang L-S Sheng L-J Zhu Z Shang L-L Gao P-L Zhang M Zhou K-G Zhou L-G Qiu Q-F Liu H-Y Zhang J-Y Li J Jin L Fu W-L Zhao J-P Chen X Du G Huang Q-F Wang J-F Zhou Source Type: research

CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment
CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment, Published online: 20 December 2017; doi:10.1038/s41408-017-0023-xCD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - December 20, 2017 Category: Hematology Authors: E. Mejstr íková O. Hrusak M. J. Borowitz J. A. Whitlock B. Brethon T. M. Trippett G. Zugmaier L. Gore A. von Stackelberg F. Locatelli Source Type: research

Marked elevation of serum lactate dehydrogenase in primary myelofibrosis: clinical and prognostic correlates
Marked elevation of serum lactate dehydrogenase in primary myelofibrosis: clinical and prognostic correlates, Published online: 18 December 2017; doi:10.1038/s41408-017-0024-9Marked elevation of serum lactate dehydrogenase in primary myelofibrosis: clinical and prognostic correlates (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - December 18, 2017 Category: Hematology Authors: Sahrish Shah Mythri Mudireddy Curtis A. Hanson Rhett P. Ketterling Naseema Gangat Animesh Pardanani Ayalew Tefferi Source Type: research

Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q)
Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q), Published online: 18 December 2017; doi:10.1038/s41408-017-0017-8Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q) (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - December 18, 2017 Category: Hematology Authors: Ayalew Tefferi Dame Idossa Terra L. Lasho Mythri Mudireddy Christy Finke Sahrish Shah Maura Nicolosi Mrinal M. Patnaik Animesh Pardanani Naseema Gangat Curt A. Hanson Rhett P. Ketterling Source Type: research

Anemia in myelofibrosis—prevalence, the U2AF1 connection, new treatments
Anemia in myelofibrosis—prevalence, the U2AF1 connection, new treatmentsAnemia in myelofibrosis—prevalence, the U2AF1 connection, new treatments, Published online: 15 December 2017; doi:10.1038/s41408-017-0032-9Anemia in myelofibrosis—prevalence, the U2AF1 connection, new treatments (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - December 15, 2017 Category: Hematology Authors: Ayalew Tefferi Source Type: research

ASXL1 c.1934dup;p.Gly646Trpfs*12—a true somatic alteration requiring a new approach
ASXL1 c.1934dup;p.Gly646Trpfs*12—a true somatic alteration requiring a new approach ASXL1 c.1934dup;p.Gly646Trpfs*12—a true somatic alteration requiring a new approach, Published online: 15 December 2017; doi:10.1038/s41408-017-0025-8 ASXL1 c.1934dup;p.Gly646Trpfs*12—a true somatic alteration requiring a new approach (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - December 15, 2017 Category: Hematology Authors: Costas K. Yannakou Kate Jones Michelle McBean Ella R. Thompson Georgina L. Ryland Ken Doig John Markham David Westerman Piers Blombery Source Type: research

Mismatched unrelated donor allogeneic stem cell transplant for high risk haematological malignancy: A single centre experience
Mismatched unrelated donor allogeneic stem cell transplant for high risk haematological malignancy: A single centre experience, Published online: 15 December 2017; doi:10.1038/s41408-017-0012-0Mismatched unrelated donor allogeneic stem cell transplant for high risk haematological malignancy: A single centre experience (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - December 15, 2017 Category: Hematology Authors: Heshani Mediwake Cameron Curley Jason Butler Angela Mclean Siok Tey Geoffrey R. Hill Anthony Morton Ashish Misra Elango Subramoniapillai Simon Durrant Glen A. Kennedy Source Type: research

Clinical and radiological responses to oral methotrexate alone or in combination with other agents in Erdheim-Chester disease
Clinical and radiological responses to oral methotrexate alone or in combination with other agents in Erdheim-Chester disease, Published online: 15 December 2017; doi:10.1038/s41408-017-0034-7Clinical and radiological responses to oral methotrexate alone or in combination with other agents in Erdheim-Chester disease (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - December 15, 2017 Category: Hematology Authors: Gaurav Goyal Mithun V. Shah Timothy G. Call C. Christopher Hook William J. Hogan Ronald S. Go Source Type: research

MYD88 mutations predict unfavorable prognosis in Chronic Lymphocytic Leukemia patients with mutated IGHV gene
MYD88 mutations predict unfavorable prognosis in Chronic Lymphocytic Leukemia patients with mutated IGHV gene, Published online: 15 December 2017; doi:10.1038/s41408-017-0014-y MYD88 mutations predict unfavorable prognosis in Chronic Lymphocytic Leukemia patients with mutated IGHV gene (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - December 15, 2017 Category: Hematology Authors: Shu-Chao Qin Yi Xia Yi Miao Hua-Yuan Zhu Jia-Zhu Wu Lei Fan Chun Qiao Wei Xu Jian-Yong Li Source Type: research

Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers
Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers, Published online: 15 December 2017; doi:10.1038/s41408-017-0030-yOutcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - December 15, 2017 Category: Hematology Authors: Tiffany Tang Lay Poh Khoo Cindy Lim Jun Soo Ham Seok Jin Kim Huangming Hong Colin Phipps Yuh Shan Lee Miriam Tao Richard Quek Mohamad Farid Tongyu Lin Won Seog Kim Soon Thye Lim Source Type: research

MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma
MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma, Published online: 15 December 2017; doi:10.1038/s41408-017-0033-8MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - December 15, 2017 Category: Hematology Authors: Suvi-Katri Leivonen Katherine Icay Kirsi J äntti Ilari Siren Chengyu Liu Amjad Alkodsi Alejandra Cervera Maja Ludvigsen Stephen Jacques Hamilton-Dutoit Francesco d ’Amore Marja-Liisa Karjalainen-Lindsberg Jan Delabie Harald Holte Rainer Lehtonen Sampsa Source Type: research

Development of expression-based biomarkers of Dasatinib response in hematologic malignancies
Development of expression-based biomarkers of Dasatinib response in hematologic malignancies, Published online: 15 December 2017; doi:10.1038/s41408-017-0013-zDevelopment of expression-based biomarkers of Dasatinib response in hematologic malignancies (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - December 15, 2017 Category: Hematology Authors: Monica K. Akre Amit Mitra Wen Wang Chad L. Myers Brian Van Ness Source Type: research

Correlation between markers of bone metabolism and vitamin D levels in patients with monoclonal gammopathy of undetermined significance (MGUS)
Correlation between markers of bone metabolism and vitamin D levels in patients with monoclonal gammopathy of undetermined significance (MGUS), Published online: 14 December 2017; doi:10.1038/s41408-017-0015-xCorrelation between markers of bone metabolism and vitamin D levels in patients with monoclonal gammopathy of undetermined significance (MGUS) (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - December 14, 2017 Category: Hematology Authors: Brea Lipe Suman Kambhampati Peter Van Veldhuizen Abdulraheem Yacoub Omar Aljitawi Joseph Mikhael Source Type: research

Clinically meaningful benefit: real world use compared against the American and European guidelines
Clinically meaningful benefit: real world use compared against the American and European guidelines, Published online: 14 December 2017; doi:10.1038/s41408-017-0009-8Clinically meaningful benefit: real world use compared against the American and European guidelines (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - December 14, 2017 Category: Hematology Authors: Jessica J. Dreicer Sham Mailankody Farhad Fahkrejahani Vinay Prasad Source Type: research

Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care, Published online: 14 December 2017; doi:10.1038/s41408-017-0018-7Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - December 14, 2017 Category: Hematology Authors: Aziz Nazha Mikkael A. Sekeres Rami Komrokji David P. Steensma Hagop Kantarjian Gail Roboz Pierre Fenaux Thomas Prebet Nozar Azarnia Patrick S. Zbyszewski Steven M. Fruchtman Valeria Santini Lewis R. Silverman Uwe Platzbecker Guillermo Garcia-Manero Source Type: research

Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data
Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data, Published online: 13 December 2017; doi:10.1038/s41408-017-0006-yEssential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - December 13, 2017 Category: Hematology Authors: Martin Schalling Andreas Gleiss Bettina Gisslinger Albert W ölfler Veronika Buxhofer-Ausch Georg Jeryczynski Maria-Theresa Krauth Ingrid Simonitsch-Klupp Christine Beham-Schmid J ürgen Thiele Heinz Gisslinger Source Type: research

Molecular predictors of post-transplant survival in acute myeloid leukemia
Molecular predictors of post-transplant survival in acute myeloid leukemia, Published online: 13 December 2017; doi:10.1038/s41408-017-0027-6Molecular predictors of post-transplant survival in acute myeloid leukemia (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - December 13, 2017 Category: Hematology Authors: Tong Qin Sun Wu Hongmian Zhao Keman Xu Huaping Fu Zhiheng Cheng Yifan Pang Yu Han Li Chen Chao Wang Yijie Zhang Xiaoyan Ke Kailin Xu Jinlong Shi Lin Fu Source Type: research

Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma
Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma, Published online: 13 December 2017; doi:10.1038/s41408-017-0026-7Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - December 13, 2017 Category: Hematology Authors: Tania Jain Hemalatha Narayanasamy Joseph Mikhael Craig B. Reeder P. Leif Bergsagel Angela Mayo A. Keith Stewart Farouk Mookadam Rafael Fonseca Source Type: research

CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles
CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles, Published online: 08 December 2017; doi:10.1038/s41408-017-0010-2 CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - December 8, 2017 Category: Hematology Authors: Roberta Zini Paola Guglielmelli Daniela Pietra Elisa Rumi Chiara Rossi Sebastiano Rontauroli Elena Genovese Tiziana Fanelli Laura Calabresi Elisa Bianchi Simona Salati Mario Cazzola Enrico Tagliafico Alessandro M. Vannucchi Rossella Manfredini Source Type: research

Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma
Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma, Published online: 05 December 2017; doi:10.1038/s41408-017-0020-0Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - December 5, 2017 Category: Hematology Authors: Daniel E. Meyers Satbir Thakur Chandini M. Thirukkumaran Don G. Morris Source Type: research

MRD in multiple myeloma: more questions than answers?
MRD in multiple myeloma: more questions than answers?, Published online: 05 December 2017; doi:10.1038/s41408-017-0028-5MRD in multiple myeloma: more questions than answers? (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - December 5, 2017 Category: Hematology Authors: Philippe Moreau Elena Zamagni Source Type: research

Signaling mechanisms that regulate ex vivo survival of human acute myeloid leukemia initiating cells
Signaling mechanisms that regulate ex vivo survival of human acute myeloid leukemia initiating cells, Published online: 30 November 2017; doi:10.1038/s41408-017-0003-1Signaling mechanisms that regulate ex vivo survival of human acute myeloid leukemia initiating cells (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - November 30, 2017 Category: Hematology Authors: Dheeraj Bhavanasi Kwun Wah Wen Xiaolei Liu Francois Vergez Gwenn Danet-Desnoyers Martin Carroll Jian Huang Peter S Klein Source Type: research

Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals
Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals, Published online: 30 November 2017; doi:10.1038/s41408-017-0008-9Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - November 30, 2017 Category: Hematology Authors: Austin Lammers Ruibin Wang Jeremy Cetnar Vinay Prasad Source Type: research